中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
27期
122-123
,共2页
左旋多巴%普拉克索%原发性帕金森病
左鏇多巴%普拉剋索%原髮性帕金森病
좌선다파%보랍극색%원발성파금삼병
Levodopa%Pramipexole%Idiopathic Parkinson disease
目的 探究左旋多巴联合普拉克索治疗原发性帕金森病的临床疗效. 方法 随机选择2013年2月-2014年2月期间该院收治的60例原发性帕金森病患者,随机平均分为观察组30例行左旋多巴联合普拉克索治疗,对照组30例行左旋多巴治疗,观察对比两组临床疗效及安全性.结果 治疗后观察组UPDRSⅡ和Ⅲ评分分别为(10.2±3.4)分和(27.6±6.5)分;对照组UPDRSⅡ和Ⅲ评分分别为(14.3±3.1)分和(33.5±6.4)分,组间比较差异均具有统计学意义,P<0.05. 两组均未发生严重药物不良反应. 结论 对原发性帕金森病患者,在常规左旋多巴治疗基础上,联合普拉克索治疗,可进一步提高临床疗效,且用药安全.
目的 探究左鏇多巴聯閤普拉剋索治療原髮性帕金森病的臨床療效. 方法 隨機選擇2013年2月-2014年2月期間該院收治的60例原髮性帕金森病患者,隨機平均分為觀察組30例行左鏇多巴聯閤普拉剋索治療,對照組30例行左鏇多巴治療,觀察對比兩組臨床療效及安全性.結果 治療後觀察組UPDRSⅡ和Ⅲ評分分彆為(10.2±3.4)分和(27.6±6.5)分;對照組UPDRSⅡ和Ⅲ評分分彆為(14.3±3.1)分和(33.5±6.4)分,組間比較差異均具有統計學意義,P<0.05. 兩組均未髮生嚴重藥物不良反應. 結論 對原髮性帕金森病患者,在常規左鏇多巴治療基礎上,聯閤普拉剋索治療,可進一步提高臨床療效,且用藥安全.
목적 탐구좌선다파연합보랍극색치료원발성파금삼병적림상료효. 방법 수궤선택2013년2월-2014년2월기간해원수치적60례원발성파금삼병환자,수궤평균분위관찰조30례행좌선다파연합보랍극색치료,대조조30례행좌선다파치료,관찰대비량조림상료효급안전성.결과 치료후관찰조UPDRSⅡ화Ⅲ평분분별위(10.2±3.4)분화(27.6±6.5)분;대조조UPDRSⅡ화Ⅲ평분분별위(14.3±3.1)분화(33.5±6.4)분,조간비교차이균구유통계학의의,P<0.05. 량조균미발생엄중약물불량반응. 결론 대원발성파금삼병환자,재상규좌선다파치료기출상,연합보랍극색치료,가진일보제고림상료효,차용약안전.
Objective To explore the clinical curative effect of levodopa combined with pramipexole in the treatment of idiopathic Parkinson's disease. Methods 60 cases treated in our hospital during February 2013-February 2014 primary Parkinson's disease (PD) patients were randomly divided into the observation group 30 cases were treated with levodopa combined with pramipexole treatment, the control group of 30 cases were treated with levodopa were compared two groups of clinical curative effect and safety. Results After treatment, the observation group UPDRSⅡ and Ⅲ scores were (10.2 ± 3.4) points and (27.6 ± 6.5) points; the con-trol group UPDRSⅡandⅢscores were (14.3 ± 3.1) points and (33.5 ± 6.4) points between the two groups the difference was sta-tistically significant, P<0.05.the two groups were not serious adverse drug reactions. Conclusion For patients with idiopathic Parkinson's disease, in regular levodopa therapy, combined treatment with pramipexole, further improve the clinical efficacy and drug safety.
